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Abstract  
Objectives:To compare the clinical benefits of granulocyte-colony stimulating factor (G-
CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) plus standard 
supportive care to supportive care alone among cancer patients with febrile neutropenia. 
Methods:Clinical data were collected retrospectively from 148 consecutive cancer patients 
with neutropenia and fever. Patients had hematologic (i.e., acute leukemias or 
lymphoproliferative disorders) or non-hematologic malignancies (i.e., solid tumors 
including carcinoma of breast, lung, or colon). Clinical variables analyzed included: age 
and sex; underlying malignancies; chemotherapy regimens; symptoms at time of 
presentation; duration of fever prior to study enrollment; days from chemotherapy until 
administration of GM-CSF or G-CSF; number of previous neutropenic episodes; duration 
of fever and day of defervescence; absolute neutrophil count on day of defervescence; 
duration of neutropenia; number and types of antibiotics used; day amphotericin B begun; 
number of culture-documented infective episodes involving bloodstream, lung, pleura, 
urinary tract, gastrointestinal tract, intravenous cannulae, or skin; types of antimicrobial 
isolates; cost of cytokine therapy; length of hospital stay and clinical outcome. 
Results:The use of myeloid growth factors increased the number of circulating peripheral 
white blood cells, but no significant effect was noted in terms of duration of neutropenia or 
fever, number of culture-proven infections (except pneumonia; p < 0.04), length of hospital 
stay, or survival. 
Conclusion:In areas with limited health care resources, expensive treatment with GM-CSF 
or G-CSF should be reserved for patients with complicated febrile neutropenia where the 
expected risk of infection is high and the documented infections that are refractory to 
antibiotic duration of neutropenia is prolonged, or those with treatment (JPMA 52: 206, 
2002). 
Introduction 
The precise role of hematopoietic growth factors in the management of patients with 
neutropenia and fever remains uncertain. Granulocyte-colony stimulating factor (G-CSF or 
filgrastin) and granulocyte macrophage-colony stimulating factor (GM-CSF or 
sargramostim) have become popular modalities used in the management of patients with 
cancer chemotherapy-induced neutropenia. A number of clinical studies have demonstrated 
the potential ability of these factors to decrease the duration of cytotoxic-induced 
neutropenia, number of febrile days and reduce hospital stay1-5. However, not all 
investigators have demonstrated substantial benefit from the use of myeloid colony 
stimulating factors6-8 and their relatively high cost must be seriously considered when 
contemplating the use of G-CSF and GM-CSF in countries like Pakistan with limited health 
care resources. In order to determine the appropriateness and cost-effectiveness of these 
cytokines in local setting, we conducted a comparative study of GM-CSF or G-CSF plus 
standard supportive care versus supportive care alone in chemotherapy-induced 
neutropenic fever and evaluated several targeted outcome measures. 
Patients and Methods 
During the period January 1997 through March 1998, clinical data were collected 
retrospectively from consecutive patients seen on the oncology service with neutropenia 
(defined as an absolute neutrophil count < 500/cu mm or between 500-1,000/cu mm but 
rapidly dropping) and fever (defined as a temperature elevation above 38.3°C. Patients had 
hematologic (i.e., acute leukemias or lymphoproliferative disorders) or nonhematologic 
malignancies (i.e., solid tumors including carcinoma of breast, lung, colon). Various 
chemotherapy regimens are shown in Table 1. 
 Conventional supportive care involved initiation of empiric two-drug antibacterial therapy 
with the development of fever (generally, piperacillin/tazobactam plus amikacin; 
vancomycin was added if patients had evidence of catheter-related infection such as signs 
of inflammation around a central or peripheral catheter, or tenderness overlying a 
subcutaneous catheter port). Empiric antifungal treatment with iv amphotericin B was 
begun if patients remained febrile for more than five days. Due to economic considerations, 
growth factors were begun at the time of development of fever rather than at the onset of 
neutropenia. Growth factors were administered in the following doses: G-CSF ugfkg] (n = 
27) or GM-CSF ug/m2} (n = 40). Therapy with growth factors was continued for a mean of 
3.93 days (range 1-9 days). 
Clinical variables analyzed included age and sex; AD = cytosine arabinoside 100 mg/rn2 x 
7d plus daunorubicin 45 mg/rn2 x 3d; ADE = cytosine arabinoside 100 mg/rn2 x 7d plus 
daunorubicin 45mg/rn2 x 3d plus etoposide 100 mg/rn2 x 4d; AM = cytosine arabinoside 
100 mg/rn2 x 7d plus mitoxantrone 12 mg/rn2 x 3d; HiD Ara-C = 1.5 gm/rn2 q12h x 3d; AC 
= adriarnycin 60mg/rn2 plus cyclophosphamide 600 mg/rn2; FAC = 5-FU 500 mg/rn2 plus 
adriamycin 50 mg/rn2 plus cyclophosphamide 500 mg/rn2; CMF = cyclophosphamide 600 
mg/rn2 plus methotrexate 40 mg/rn2 plus 5-FU 600 mg/ m2; AN = adriamycin 50mg/rn2 
plus nanelbine 30 mg/rn2, AT = adriamycin 50 mg/rn2 plus docetaxel 75mg/rn2; Paclitaxel 
175 mg/rn2; NVB + CDDP = nanelbine 25 mg/rn2 day I & day 8 plus cisplatin 100 mg/rn2; 
CHOP = cyclophospharnide 750 mg/rn2 plus adriamycin 50mg/rn2 plus vincristine 1.4 mg 
plus prednisolone 60 mg; ABUD = adriamycin 25 mg/rn2 plus bleomycin 10 mg/rn2 plus 
vinblastine 6 mg/rn2 plus DTIC 375 mg/rn2; COPP cyclophosphamide 650 mg/rn2 plus 
vincristine 1.4 rng plus procarbazine 100 mg/rn2 x l4d plus prednisolone 40 mg ; Cyclo + 
Carbo Platin = cyclophosphamide 750 mg/rn2 plus carboplatinum AUC5; Taxol + Carbo = 
taxol 135 mg plus carboplatinum AUC 5; BEP = bleomycin 30 rng days 1, 8, and 15 plus 
etoposide 100 mg/rn2 x 5d plus cisplatin 20 mg/rn2 x 5d; CDDP + 5FU cisplatin 100 mg/rn2 
plus 5-FU 1 gm/m2 x 4 days; 1 fos + DOX = 1 fosfomide 3 gm/rn2 x 3d plus doxorubicin 
20 mg/rn2 x 3 days; I fos + Etoposide = I fosfdmide 2 gm/rn2 x 3d plus etoposide 100 
mg/rn2 x 3d; ICE 1 fosfomide 1.2 gm/rn2 x 5d plus carboplatinum 400 mg/rn2 plus 
etoposide 100 mg/rn2 x 5d. 
symptoms at time of presentation; duration of fever prior to study enrollment; days from 
chemotherapy until admission; number of previous neutropenic episodes; duration of fever 
and day of defervescence; absolute neutrophil count on day of defervescence; duration of 
neutropenia; number and types of antibiotics used; day amphotericin B begun; number of 
culture-documented infective episodes involving bloodstream, lung, pleura, urinary tract, 
gastrointestinal tract, intravenous cannulae, or skin; types of antimicrobial isolates; cost of 
cytokine therapy; length of hospital stay and clinical outcome. 
Statistical Methods 
Data were summarized as means with standard deviation, or medians with ranges (for 
continuous variables) and as frequencies and percentages (for categorical variables). 
Univariate analysis was performed using a two independent sample t-test, Pearson’s chi-
square and Fisher’s exact test wherever appropriate. A p value < 0.05 was considered 
statistically significant. Analyses were carried out using the statistics software program 
SPSS (release 8.0.0, standard version, copyrightO SPSS Inc.).  
 
Results  
Demographic and clinical variables for the two study groups are shown in Table 2. 
 
The groups were comparable in terms of numbers and percentages of hematologic and non-
hematologic malignancies, days until fever, presenting symptoms, and absolute neutrophil 
count at the time of fever. A significantly higher proportion of patients in the group 
receiving growth factors had experienced previous episodes of febrile neutropenia. 
Clinical outcomes 
The absolute neutrophil count on the day of defervescence was higher in the growth factor-
treated group although the difference was not statistically significant (Table 3). 
 Requirements for antimicrobial agents were not significantly different (data not shown), 
Patients treated with growth factors took more than one day longer to achieve 
defervescence and also remained in the hospital one day longer (p < 0.008 and p < 0.018, 
respectively). Six patients (9%) in the cytokine treatment group and 13 (16%) in the control 
group died during febrile neutropenia (not statistically significant). 
Sites of infection and recovery of pathogens 
The numbers and types of clinically relevant infections and the recovery of pathogens from 
blood, stool and several other body sites were comparable between the two groups. 
However, more subjects in the cytokine-treated group had urinary tract infections (10 
versus 4; p <0.05), while a significantly higher number of patients in the control group 
were found to have pneumonia; overall, 15 patients developed radiographic evidence of 
pulmonary infiltrates, 11 of  cytokine therapy (p = 0.026). The incidences of pleural 
effusions on chest x-ray were similar. 
A total of 68 microbiologic isolates were cultured during 148 episodes of febrile 
neutropenia (46% yield) (Table 4). 
 Overall the numbers of bacterial and fungal pathogens isolated from the two study groups 
were comparable (Table 4). Aerobic Gram-negative bacteria were most commonly isolated 
from both the treatment and control groups (22 versus 17 isolates, respectively); fewer 
gram-positive bacteria were isolated from patients treated with growth factors (not 
significant). 
Discussion  
Despite their widespread popularity in oncologic practice, there is a lack of published data 
demonstrating clear survival benefits. Therfore the routine use of costly hematopoietic 
colony stimulating factors as adjuvant therapy for neutropenic patients with unexplained 
fever is not currently recommended9. The administration of G-CSF and GM-CSF in many 
of the studies has demonstrated a reduction in the days to neutrophilic recoveiy and a 
reduction of morbidity10-13. Rowe and associates used GM-CSF in older patients with acute 
myeloid leukemia; the remission rate was 60% and 44% in the placebo group. Beneficial 
effects including survival were also demonstrated in the GM-CSF arm. All these patients 
had a day ten bone marrow performed and only if there were no leukemic cells in the 
marrow was randomization done12. 
In the present study of febrile patients recently undergoing induction chemotherapy, neither 
GM-CSF nor G-CSF significantly reduced the duration of neutropenia or fever, decreased 
the incidence of culture-proven infective episodes (except pneumonia), reduced the 
duration of hospitalization, or improved overall clinical outcomes. 
In an attempt to maximize patient benefits and minimize adverse effects on health care 
systems and society, the American Society of Clinical Oncology (ASCO) and the 
Infectious Diseases Society of America have published consensus guidelines for the 
rational use of these agents with cancer chemotherapy and febrile neutropenia9,13. It should 
be emphasized, however, that for many of these recommendations data from randomized 
clinical trials are not available. The use of myeloid stimulating factors in cancer 
chemotherapy induction is not routinely recommended but instead is based on risk 
stratification of patients, itself being dependent on a number of clinical variables. For 
certain conditions where worsening of the clinical course is predicted and there is an 
expected long delay in recovery of the marrow, one of these agents may be indicated. Such 
conditions include pneumonia, hypotensive episodes, severe cellulitis or sinusitis, systemic 
fungal infections and multiorgan dysfunction secondary to sepsis. Therapy with colony-
stimulating factors may also be considered in patients who remain severely neutropenic and 
have documented infections that fail to respond to appropriate antimicrobial treatment9,13. 
There are several limitations of this study; firstly, data were collected retrospectively and 
hence randomization was not possible. However, since the data were collected from 
consecutive patients presenting over a short study period of 14 months, it minimized the 
effects of several potential confounding variables. The short study period meant that 
variations in certain variables (e.g., types of underlying cancers, chemotherapy dose-
intensities, patterns of microbial pathogen isolation and antibiotic resistance, use of 
antifungal prophylaxis, and choices of empiric antimicrobial therapy) were notably limited. 
Furthermore, the decision to use or not use growth factors (before and during the study) 
was based purely on the basis of financial affordability by the patient, and thus may have 
reduced potential bias in patient selectiOn. Another limitation of the study is that data for 
G-CSF and GM-CSF were combined, although cytokine selection was made randomly. 
Nevertheless, although some reports have suggested that G-CSF may result in a faster 
neutrophil recovery compared to GM-CSF, this has not been a consistent finding and no 
significant differences between the two agents have been reported for clinically-relevant 
end points such as the infectious complications, length of hospitalization, use of antibiotics, 
hospital costs and mortality. 
Thirdly, treatment with growth factors was begun a mean of 11 and 13 days post-
chemotherapy in respective study groups and patients generally had experienced 
neutropenia several days before the development of fever. This delayed initiation of 
cytokine therapy was not because study subjects had low-risk (delayed-onset) neutropenia 
but was due to the financial limitations of our patients. This practice is in line with ASCO 
guidelines9. 
In poorer countries like Pakistan very expensive therapeutics may adversely affect the 
economics of the patient, family and society. In our setting the use of GMCSF and G-CSF 
must be governed by proven efficacy, specific indications and cost-effectiveness. The 
results of our study indicate that these cytokines may not confer significant benefits to 
patients with uncomplicated febrile neutropenia and according to current guidelines should 
be reserved for complicated cases where the expected risk of infection is high and the 
duration of neutropenia is prolonged, or for patients with documented infections that are 
refractory to antibiotic treatment. 
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